We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




In Breast Cancer a Calcium Pump Works both Ways

By LabMedica International staff writers
Posted on 08 Nov 2010
Cancer researchers have identified a protein overexpressed in breast cancer cells that functions both as a calcium pump and as a component of a signaling system, which triggers a massive cellular influx of calcium.

The protein, Secretory Pathway Ca2+-ATPase (SPCA2), was thought to be a supplemental protein pump – one of several able to force calcium ions out of the cell. More...
However, a study published in the October 1, 2010, issue of the journal Cell revealed that SPCA2 primarily acted in an opposite fashion.

Investigators at Johns Hopkins University (Baltimore, MD, USA) showed that in breast cancer cells SPCA2 moved from its normal location in the cytoplasm to the cell surface, where it interacted with calcium channels. SPCA2 activated the channels, admitting large quantities of calcium into the cells.

The action of SPCA2 in breast cancer cells was thought to have derived from a possible role in lactation, a function of normal breast tissue. "Human milk is extremely high in calcium, and all that calcium gets there because SPCA2, along with an elaborate network of other proteins, is turned on during lactation,” explained senior author Dr. Rajini Rao, professor of physiology at Johns Hopkins University. "SPCA2's normal purpose, we think, is to signal calcium channels to open so lots and lots of calcium come into the cells of mammary tissue, where it is packaged and pumped out to the milk.”

The SPCA2 gene is down regulated in normal breast tissue except during lactation. However, it is highly up regulated in breast cancer cells. "When regulation of SPCA2 goes wrong, that is when you have breast cancer,” said Dr. Rao, "probably because in breast tumor cells, the lack of regulation of the pump/signaling mechanism lets vast amounts of calcium into the cells, which stimulates the cell cycle, and triggers high levels of proliferation.”

Related Links:
Johns Hopkins University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.